

TABLE OF CONTENTS

January 12, 2009

No. 2122

BUSINESS

- 1 Take Risk to Develop Breakthrough Drugs: FPMAJ President Dr Takenaka
- 2 Aricept Moves Up to 3rd Place in Domestic Drugs Sales Ranking
 - Olmetec Rises to 2nd Place among ARBs
- 3 Daiichi Sankyo to Report Valuation Loss of ¥354 Bil.
- 3 Indirect Divisions to Support MRs at Novo Nordisk
- 6 Kyowa Kirin to Transfer Neu-Up to Avoid Problems with AML
- 6 MediciNova Proposes Acquisition to Avigen
 - Licensing of MN-166 Being Delayed
- 7 **Commentary**
 - Aiming at Further Growth beyond Global Recession
- 8 MTPC Transfers Shares of API to MCC
 - Acquiring Chosei Yakuhin to Enhance Presence in Market for Generics
- 8 Novartis, Mochida Terminate Copromotion of Diovan
- 8 **BUSINESS NEWS IN BRIEF**
 - Kringle Pharma Creates Subsidiary in Stockholm
 - Hokuyaku Takeyama HD to Remain Independent: President Manabe

REGULATORY

- 9 Prasugrel to Be Reviewed in US in February
- 9 Omalizumab, Maraviroc, Nalfurafine Recommended for Approval
- 10 *Koroshō's* General Account Budget for FY2009 Increased to ¥25,156.8 Bil.
 - Budget to Promote Use of Generics Tripled to ¥920 Mil.
- 10 FY2009 Budget Proposal Includes ¥24,592 Bil. for Social Security
 - ¥310 Mil. to Promote Use of Generics
- 11 METI to Earmark ¥4.3 Bil. to Develop Regenerative Medicine Technology
- 11 **REGULATORY NEWS IN BRIEF**
 - Pfizer's Anti-HIV Agent Celsentri Approved
 - Nateglinide Approved for Use in Combination with TZD
 - Combination of Actos and Biguanides Approved
 - GSK Applies for Levocetirizine in Japan
 - Wyeth Submits MAA for 13-Valent Vaccine in EU
 - Takeda Receives New Action Date for Alogliptin NDA
 - Approval of Intanza/IDflu Vaccine Recommended in EU: Sanofi Pasteur
 - Baxter Receives EMEA Positive Opinion for CELVAPAN
 - Nexavar Precautions Revised Because of 2 Deaths
 - JSGO Calls For Obligatory HPV Vaccination Program

R&D

- 14 Takeda Begins PIII Trial of ATL-962 for Obesity Licensed from Alizyme

- 14 Daiichi Sankyo to Cooperate with Kitasato Institute to Develop Vaccines
- 14 PSJ Symposium Calls on Researchers to Work in New Fields
 - True Therapeutic Effects Should Be Demonstrated: Dr Ohkawa of Takeda
 - Management Was About to Drop Vesicare at One Time: Astellas
- 16 **R&D NEWS IN BRIEF**
 - Meiji Seika Discontinues Development of Carbapenem
 - Council Calls For Early Approval of Tetrabenzazine for Huntington's Chorea
 - Losartan Decreases Uric Acid Levels *In Vivo*
 - 86% of Patients Survive in 7th Year of Glivec Treatment

GENERICS

- 18 Market for Generics to Expand to ¥359.7 Bil. in 2010
- 18 *Koroshō* to Educate Doctors on Benefits of Generics
- 18 New Management Team Members Appointed for Ranbaxy

MEDICAL DEVICES

- 19 Business Strategy for 2009 Announced by Agilent Technologies
 - Enhancing Life Science Business
 - Contracts with New Distributors in Life Science Market
 - Upgrading Marketing Support Function
 - Global Life Science Market Totals US\$18.4 Bil.
- 20 RDKK Launches Titanium Series of Reagent Kits for Its Genome Sequencer FLX
- 20 GEYMS Launches New Models in Signa MRI Series
- 20 **MEDICAL DEVICE NEWS IN BRIEF**
 - RDKK Completes Acquisition of Ventana Japan
 - NCVC Looking into Death of Young Man following Implantation of LVAS

SELF-MEDICATION

- 21 *Koroshō* to Restrict Online Sales of Drugs to Class 3 Products
 - Council Excludes Online Sales of Drugs from Its Recommendation
- 21 "Medwatcher Japan" Asks *Koroshō* to Conduct Survey on Online Sales of Drugs
- 22 Consumer, Patient Groups Present Questions to Rakuten
- 22 **SELF-MEDICATION NEWS IN BRIEF**
 - Ain to Jointly Open New Store in Sapporo with Seven & i

Seminar

- 23 Seminar
 - Hib Vaccine and Prevenar Should Eliminate Pediatric Bacterial Meningitis
 - Asthma Patients Look to New Drugs such as Omalizumab